Aptevo Therapeutics Inc (APVO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.87 (+1.63%), Market cap $0.01B, 52-week low–high $0.28 ~ $9.83.
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for t
Financial statements, price targets, institutional (13F) holdings and related news for Aptevo Therapeutics Inc are updated in real time on BlackAll Trade.
Aptevo Therapeutics Inc trades at $1.87 (+1.63%). Real-time quotes and charts are available on BlackAll Trade.
Aptevo Therapeutics Inc has a market cap of about $0.01B.
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United